{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:05:05Z","timestamp":1792800305183,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473553 and 82273556"],"award-info":[{"award-number":["82473553 and 82273556"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Excellent Youth Foundation of Sichuan Province of China","award":["2025NSFJQ0070"],"award-info":[{"award-number":["2025NSFJQ0070"]}]},{"name":"the Project of \u20180\u20131\u2019 of Sichuan University","award":["2022SCUH0033"],"award-info":[{"award-number":["2022SCUH0033"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Med-X Center for Informatics Funding Project","award":["YGJC004"],"award-info":[{"award-number":["YGJC004"]}],"id":[{"id":"https:\/\/ror.org\/04663jx74","id-type":"ROR","asserted-by":"crossref"}]},{"name":"he 1.3.5 Project for Disciplines of Excellence Clinical Research Incubation Project of West China Hospital of Sichuan University","award":["2023HXFH004"],"award-info":[{"award-number":["2023HXFH004"]}],"id":[{"id":"https:\/\/ror.org\/007mrxy13","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the 1.3.5 Project for Disciplines of Excellence Clinical Research Interdisciplinary Innovation Project of West China Hospital of Sichuan University","award":["ZYJC21060"],"award-info":[{"award-number":["ZYJC21060"]}],"id":[{"id":"https:\/\/ror.org\/007mrxy13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early oral propranolol for infantile hemangioma (IH) can improve the success rate. However, few studies have been conducted on the specific age threshold for initiating treatment with propranolol. This study aimed to determine the cutoff value of treatment success for IH with oral propranolol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study involving 207 patients with IH and clinical data.The primary outcome measure was treatment success with oral propranolol at months 6 to 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariate analysis showed that age at treatment initiation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), high-risk IH (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002), and segmental IH (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012) were independent risk factors for treatment unsuccess with oral propranolol at months 6 to 12. Receiver operating characteristic (ROC) curve analysis indicated that the cutoff value for age at treatment initiation was 69.5 days for all patients, 65.5 days for patients with segmental IH or high-risk IH, and 93.5 days for patients with non-high-risk and nonsegmental IH. Patients who started treatment before 69.5 days had a success rate of 73.8%, which was higher than the 28.4% success rate of patients who started treatment after 69.5 days. The median time to treatment success for patients who started treatment before 69.5 days was 11.5 months, which was shorter than the 15 months for patients who started treatment after 69.5 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The initiation of treatment for IH with oral propranolol before 70 days of age can improve the success rate and shortens treatment duration, especially for segmental IH and high-risk IH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-025-06033-5","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:56:19Z","timestamp":1758740179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Timing of treatment with oral propranolol for infantile hemangioma"],"prefix":"10.1186","volume":"25","author":[{"given":"Kaizhi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"6033_CR1","doi-asserted-by":"publisher","first-page":"117181","DOI":"10.1016\/j.biopha.2024.117181","volume":"178","author":"S Xiang","year":"2024","unstructured":"Xiang S, Gong X, Qiu T, Zhou J, Yang K, Lan Y, et al. Insights into the mechanisms of angiogenesis in infantile hemangioma. Biomed Pharmacother. 2024;178:117181.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"6033_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","volume":"147","author":"Y Ji","year":"2021","unstructured":"Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, et al. Efficacy and safety of propranolol vs Atenolol in infants with problematic infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;147(7):599\u2013607.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"6033_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/bjd.12804","volume":"170","author":"A Munden","year":"2014","unstructured":"Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907\u201313.","journal-title":"Br J Dermatol"},{"issue":"1","key":"6033_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-018-0928-x","volume":"13","author":"F Hou","year":"2018","unstructured":"Hou F, Dai Y, Fan CY, Suen JY, Richter GT. Estrogen is involved in hemangioma regression associated with mast cells. Orphanet J Rare Dis. 2018;13(1):181.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"6033_CR5","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","volume":"136","author":"DH Darrow","year":"2015","unstructured":"Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136(4):e1060\u2013104.","journal-title":"Pediatrics"},{"issue":"10089","key":"6033_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85\u201394.","journal-title":"Lancet"},{"issue":"6","key":"6033_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaad.2021.08.019","volume":"85","author":"AI Rodr\u00edguez Bandera","year":"2021","unstructured":"Rodr\u00edguez Bandera AI, Sebaratnam DF, Wargon O, Wong LF. Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021;85(6):1379\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"6033_CR8","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Dumas E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351.","journal-title":"N Engl J Med"},{"issue":"6","key":"6033_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2021.08.020","volume":"85","author":"DF Sebaratnam","year":"2021","unstructured":"Sebaratnam DF, Rodr\u00edguez Bandera AL, Wong LF, Wargon O. Infantile hemangioma. Part 2: management. J Am Acad Dermatol. 2021;85(6):1395\u2013404.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"6033_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.abd.2022.04.008","volume":"98","author":"A Giachetti","year":"2023","unstructured":"Giachetti A, D\u00edaz MS, Boggio P, Posadas Mart\u00ednez ML. Early propranolol treatment of infantile hemangiomas improves outcome. Bras Dermatol. 2023;98(3):310\u20135.","journal-title":"Bras Dermatol"},{"issue":"1","key":"6033_CR11","doi-asserted-by":"publisher","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","volume":"143","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475.","journal-title":"Pediatrics"},{"issue":"1","key":"6033_CR12","first-page":"1","volume":"20","author":"Group of Hemangioma vascular Malformation, Plastic Surgery Society, Chinese Medical Association","year":"2024","unstructured":"Group of Hemangioma vascular Malformation, Plastic Surgery Society, Chinese Medical Association. Xiaoxi, lin. Guidelines for diagnosis and treatment of hemangiomas and vascular malformations (2024 edition) [J]. J Tissue Eng Reconstr Surg. 2024;20(1):1\u201350.","journal-title":"J Tissue Eng Reconstr Surg"},{"issue":"8","key":"6033_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/ped.13318","volume":"59","author":"T Kaneko","year":"2017","unstructured":"Kaneko T, Sasaki S, Baba N, Koh K, Matsui K, Ohjimi H, et al. Efficacy and safety of oral propranolol for infantile hemangioma in Japan. Pediatr Int. 2017;59(8):869\u201377.","journal-title":"Pediatr Int"},{"issue":"2","key":"6033_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/pde.15198","volume":"40","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2023","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Frieden I, Delarue A. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate. Pediatr Dermatol. 2023;40(2):261\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"6033_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"6033_CR16","doi-asserted-by":"publisher","first-page":"e20173866","DOI":"10.1542\/peds.2017-3866","volume":"142","author":"E Baselga","year":"2018","unstructured":"Baselga E, Dembowska-Baginska B, Przewratil P, Gonz\u00e1lez-Ense\u00f1at MA, Wyrzykowski D, Torrelo A, et al. Efficacy of propranolol between 6 and 12 months of age in High-Risk infantile hemangioma. Pediatrics. 2018;142(3):e20173866.","journal-title":"Pediatrics"},{"issue":"2","key":"6033_CR17","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2011-3683","volume":"130","author":"MM Tollefson","year":"2012","unstructured":"Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents\u2019 photographs tell Us. Pediatrics. 2012;130(2):e314\u201320.","journal-title":"Pediatrics"},{"issue":"2","key":"6033_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1542\/peds.2007-2767","volume":"122","author":"LC Chang","year":"2008","unstructured":"Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360\u20137.","journal-title":"Pediatrics"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06033-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-06033-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06033-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:56:20Z","timestamp":1758740180000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-06033-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6033"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-06033-5","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of West China Hospital of Sichuan University (number: 2017414) and was carried out in accordance with the Helsinki Declaration. Due to the retrospective design of this study and the complete anonymization of all data, the Ethics Committee of West China Hospital of Sichuan University granted a waiver of the requirement for informed consent from the parents or legal guardians of the children involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"684"}}